Evidence map›Paper›PMID 28003545›Full record

ArticleScience translational medicine2016

Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM.

Dimitrios Mathios, Jennifer E Kim, Antonella Mangraviti, Jillian Phallen, Chul-Kee Park, Christopher M Jackson, Tomas Garzon-Muvdi, Eileen Kim, Debebe Theodros, Magdalena Polanczyk and 8 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 180 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
180citing papers in PubMed, 2 pooled it
12.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

180 citing papers in PubMed, 2 syntheses or guidelines pooled it, 296 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Overcoming Drug Resistance by Paclitaxel Resistance in Triple-Negative Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. The Application of PD-1 Inhibitors in Immunotherapy for Glioblastoma.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

120 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 2 countries.

Dimitrios MathiosDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Jennifer E KimDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Antonella MangravitiDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Jillian PhallenDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Chul-Kee ParkDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Christopher M JacksonDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Tomas Garzon-MuvdiDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Eileen KimDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Debebe TheodrosDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Magdalena PolanczykDepartment of Cancer Immunology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Allison M MartinDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Ian SukDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Xiaobu YeDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Betty TylerDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Chetan BettegowdaDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Henry BremDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Drew M PardollDepartment of Cancer Immunology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Michael LimDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. mlim3@jhmi.edu.
Johns Hopkins University · USJohns Hopkins Medicine · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Medical Scientist Training ProgramT32GM136577 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI ANDREA L COX · 2020 to 2026
$13.4M
NCI NIH HHS P30 CA006973NIGMS NIH HHS T32 GM136577
6 · The paper itself

Abstract

The immunosuppressive effects of chemotherapy present a challenge for designing effective cancer immunotherapy strategies. We hypothesized that although systemic chemotherapy (SC) exhibits negative immunologic effects, local chemotherapy (LC) can potentiate an antitumor immune response. We show that LC combined with anti-programmed cell death protein 1 (PD-1) facilitates an antitumor immune response and improves survival (P < 0.001) in glioblastoma. LC-treated mice had increased infiltration of tumor-associated dendritic cells and clonal expansion of antigen-specific T effector cells. In comparison, SC resulted in systemic and intratumoral lymphodepletion, with decreased immune memory in long-term survivors. Furthermore, adoptive transfer of CD8

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, NeoplasmAntineoplastic AgentsBrain NeoplasmsCarmustineCell Line, TumorDisease Models, AnimalDisease ProgressionFemaleFlow CytometryGlioblastomaGliomaHumansImmunosuppressive AgentsImmunotherapyAntibodies, MonoclonalAntibodies, NeoplasmAntineoplastic AgentsCarmustineImmunosuppressive AgentsPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Identifiers

PMID28003545
PMCPMC5724383
OpenAlexW2563647161

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.